Trial Profile

An Open, Single-arm Clinical Study Evaluating the Safety and Efficacy of IBI346 Infusion in Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 346 (Primary)
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

15 Jun 2023 Results assessing preliminary safety, tolerability, antitumor activity, and pharmacokinetic characteristics from the dose escalation parts of NCT05270928 and NCT05266768 study presented at the 28th Congress of the European Haematology Association.
23 Nov 2022 According to ClinicalTrials.gov record, protocol has been amended due to change in primary endpoint which changes the trial focus of the study from TU to AR.
23 Nov 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com